ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]
The ADA Just Rewrote Its Standards of Care. It Still Won’t Reverse Diabetes.
The most influential diabetes document in America just dropped. The American Diabetes Association’s 202 Standards of Care in Diabetes — published in December 2025 in Diabetes Care (Volume 49, Supplement 1) and now in effect across U.S. endocrinology practices — is the annual clinical playbook that 90%+ of American endocrinologists follow when treating Type 2 […]
Once-Weekly Insulin Is Here. It’s Still Not Reversal.
The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week instead of seven. For the […]
This New GLP-1 Pill Hit 89.6% A1c Goal — It Doesn’t Reverse Diabetes
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up […]
UK Doctors Just Made GLP-1s First-Line. 17,000 Lives Saved — and Counting
The UK’s National Institute for Health and Care Excellence (NICE) just rewrote the rulebook for Type 2 diabetes. As of this year, GLP-1 receptor agonists and SGLT-2 inhibitors are being prescribed earlier, faster, and to more patients than ever before — and the agency estimates this shift could prevent around 17,000 deaths over the next […]
Retatrutide Matches Bariatric Surgery: What Diabetics Should Know
New long-term data from the TRIUMPH-1 extension trial — presented at the American Diabetes Association’s 2026 Scientific Sessions — shows retatrutide drove an average of 30.3% body weight loss a 104 weeks, and 65% of participants dropped below the obesity threshold entirely. That puts a weekly injectable in the same conversation as gastric bypass and […]
Lilly’s GLP-1 Pill Just Beat Oral Ozempic – It Still Won’t Reverse Diabetes
The race for the first true GLP-1 pill just ended — and it wasn’t even close. Eli Lilly‘s once-daily oral GLP-1,orforglipron, just published head-to-head Phase 3 data showing it beat oral semaglutide (the pill form ofOzempic) on both A1c and weight loss. The results dropped this week in The Lancet, with a separate Phase 3study […]
The New GLP-1 Pill Won’t Reverse Your Type 2 Diabetes
AstraZeneca just reported phase 2 results for a new once-daily GLP-1 pill called elecoglipron. The numbers look great on the surface. The question the press is not asking: does it actually reverse the disease? What the New Study Shows AstraZeneca’s elecoglipron is a once-daily oral GLP-1 receptor agonist — the first of its kind in […]
Sleep Apnea and the Root Cause Conversation
The data is now a year old, but it has not been absorbed. In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial results: tirzepatide, the GLP-1/GIP drug sold as Mounjaro and Zepbound, reduced sleep apnea severity by roughly 50% in adults with obesity. The 52-week, placebo-controlled study showed reductions in the […]
ADA 2026: New GLP-1 Drops A1c 2.2% — Now the Hard Question
The American Diabetes Association’s 86th Scientific Sessions wrapped last week in New Orleans, and the loudest headline came from Pfizer’s phase 2b VESPER-2 trial of berobenatide, a once-weekly and once-monthly GLP-1 showing a 2.2% A1c reduction and double-digit weight loss in people with Type 2 diabetes — with no plateau in sight. It’s a real […]